Business

Johnson & Johnson recently announced its plan to pay $6.5 billion over 25 years to resolve the majority of lawsuits in the United States alleging that its talc-based products led to ovarian cancer. This move comes in the wake of mounting legal and financial challenges faced by the company due to these claims. Despite maintaining
0 Comments
In a significant legal development, a federal judge in New Jersey dismissed the legal challenges posed by Johnson & Johnson and Bristol Myers Squibb against the Biden administration’s Medicare drug-price negotiations. This ruling confirms the constitutionality of the program and represents a victory for the White House in its ongoing battle against major drug manufacturers.
0 Comments
As Paramount Global gears up to announce the departure of Chief Executive Officer Bob Bakish, the company is on the cusp of a major transformation. The move, strategically timed before an earnings report and potential merger agreement, has raised eyebrows among shareholders and industry insiders alike. While the exact reasons behind Bakish’s impending exit remain
0 Comments
The Food and Drug Administration recently approved Pfizer’s new treatment for a rare genetic bleeding disorder, marking a significant milestone for the company. The drug, known as Beqvez, is the first gene therapy from Pfizer to receive clearance in the United States. This innovative treatment is targeted towards adults with moderate to severe hemophilia B
0 Comments
An analysis released by the health policy research organization KFF revealed that more than 3 million people with Medicare could potentially be eligible for coverage of Wegovy, a newly approved weight loss drug that also benefits heart health. While this is a positive development, there are still some challenges and limitations that eligible beneficiaries may
0 Comments
PepsiCo recently released its quarterly earnings report which exceeded analysts’ expectations in both revenue and earnings per share. Despite facing challenges such as weaker U.S. demand due to recalls and backlash on pricing, the company managed to report earnings per share of $1.61, surpassing the $1.52 expected. Additionally, the revenue of $18.25 billion also exceeded
0 Comments